Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT01354392Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of barasertib in diffuse large B-cell lymphoma (DLBCL), sponsored by Oxford University Hospitals. Primary endpoint: Overall Response Rate. Started Sep 2011; status: completed.
02
Drugs
barasertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01354392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01354392.